Home Tags ABBV-3373

Tag: ABBV-3373

Photo: AbbVie R&D has focused on developing biologics. In particular, antibody therapeutics have been proven to be clinically effective for disease areas such as oncology and immunology. Photo courtesy: © 2019 - 2020 AbbVie

Beyond Oncology: ABBV-3373 Shows Improvement in Disease Activity in Phase IIa...

Peter Hofland
Research linked to the development of Antibody-drug Conjugates (ADC) for the treatment of human diseases has, for decades, been focused on oncology and hematological...

How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads...

Jon Gingrich
Antibody-drug Conjugates or ADCs combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise, targeted, therapeutic applications. Combining the...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X